Summit-based Celgene Corp. announced it has acquired Juno Therapeutics Inc.
As a result, Juno common stock will no longer be listed for trading on the NASDAQ.
The acquisition, Celegene said, positions it as a lead in the cellular immunotherapy industry. Per the deal, Celgene is adding novel technologies and advanced cellular manufacturing capabilities to its portfolio. Celgene also gains full rights to JCAR017 (lisocabtagene maraleucel; liso-cel), a CD-19 targeted CAR T therapy currently in trials for relapsed and/or refractory diffuse large B-cell lymphoma.
Celegne said it expects the addition of JCAR017 and other immunotherapy products in Juno’s pipeline to help accelerate revenue in 2020 and beyond.
“Our colleagues at Juno are developing some of the most promising approaches to treating cancer, and we are excited to add their pioneering work to Celgene’s leading hematology and oncology research and commercial platform,” said Mark J. Alles, chairman and CEO of Celgene.
“Together, we expect to expand our opportunities to discover and develop new therapies that will improve and extend the lives of patients worldwide.”